10 Best Penny Stocks to Buy and Hold Under $5

In this article, we will look at the 10 Best Penny Stocks to Buy and Hold Under $5.

Smaller companies have started to attract more attention on Wall Street. After years in which mega-cap technology names drove most of the market’s gains, investors are taking a closer look at areas that were largely left behind. Many of these businesses are operating in fast-growing niches, yet still remain relatively underfollowed by large institutional investors.

That is also the message coming through in the asset-manager commentary. Franklin Templeton says “both small-cap quality and value are poised for meaningful rebounds in 2026” and adds that “the current period” is “an opportune time to invest in select small-caps for the long run.” AllianceBernstein makes a similar point from a macro angle, arguing that “the tide may be turning” and that “Attractive valuations are finally being accompanied by earnings growth expected to surpass large-caps.” Janus Henderson adds that “multiple drivers beyond interest rates support small caps heading into 2026,” while “small-cap valuations remain historically cheap relative to large caps” and earnings growth is “converging with large-cap levels.” Put together, the case is not just that small stocks are cheaper. It is that parts of the small-cap universe may now have a more durable earnings and valuation setup than they have had in years.

This article is less about chasing volatility and more about finding smaller names that may have better prospects than the market is giving them credit for. With that in mind, let’s take a look at the 10 Best Penny Stocks to Buy and Hold Under $5.

Our Methodology

We used the Finviz screener to identify stocks that are trading below $5 per share and are viewed favorably by analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Evotec SE (NASDAQ:EVO)

On April 14, 2026, H.C. Wainwright assumed coverage of Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target, citing the company’s shift from a legacy asset-heavy integrated model toward a more streamlined and capital-efficient structure. The firm views current share levels as an attractive entry point for long-term investors.

On the same day, Evotec SE (NASDAQ:EVO) announced the appointment of Ingrid Müller as Chief Operating Officer, effective May 1. She will join the company’s management board and oversee global operations as well as the execution of Evotec’s Horizon initiative. Müller most recently served as VP of portfolio strategy and execution at CureVac.

Last month, Deutsche Bank analyst Fynn Scherzler lowered the price target on Evotec SE (NASDAQ:EVO) to €4.50 from €6 previously and maintained a Hold rating on Evotec SE (NASDAQ:EVO) shares.

Evotec SE (NASDAQ:EVO) provides drug discovery and development services across multiple therapeutic areas globally.

9. Arbutus Biopharma Corporation (NASDAQ:ABUS)

On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, a step that could help accelerate its development and review timeline.

On April 6, 2026, Jefferies lowered its price target on Arbutus Biopharma Corporation (NASDAQ:ABUS) to $5.50 from $7 while maintaining a Buy rating, citing updated assumptions around the outcome of Moderna’s appeal tied to their legal settlement. The firm raised its estimated probability of Moderna prevailing under 28 U.S.C. Section 1498 to 75% from 25%, which would impact the contingent $1.3B payment.

Last month, Arbutus and Genevant Sciences, a subsidiary of Roivant Sciences, reached a global settlement with Moderna valued at up to $2.25B related to the use of lipid nanoparticle (LNP) technology in COVID-19 vaccines. The agreement includes a $950M upfront payment scheduled for July 2026 and an additional $1.3B contingent on the appellate ruling. The settlement also includes licensing terms, with Moderna receiving a non-exclusive global license for LNP technology in infectious disease applications.

Arbutus Biopharma Corporation (NASDAQ:ABUS) develops therapies targeting infectious diseases, including chronic hepatitis B.

8. Allogene Therapeutics, Inc. (NASDAQ:ALLO)

On April 15, 2026, H.C. Wainwright lowered its price target on Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $11 from $12 while maintaining a Buy rating following the pricing of its previously announced $175M common stock offering. The firm said the recent share pullback appears “unwarranted” and views it as an attractive entry point.

Meanwhile, Jefferies analyst Roger Song raised his price target to $10 from $6 and kept a Buy rating after interim data from the Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma exceeded expectations. The firm sees meaningful upside potential based on the early results.

On April 12, 2026, Allogene reported data from a planned interim futility analysis of the ALPHA3 trial. At the protocol-defined cutoff—triggered when the 24th patient completed a Day 45 MRD assessment—58.3% of patients treated with cema-cel achieved minimal residual disease (MRD) negativity versus 16.7% in the observation arm, a 41.6 percentage point difference. Prior literature suggests that a 25%–30% MRD clearance gap could translate into meaningful clinical benefit. Plasma ctDNA levels declined by a median of 97.7% from baseline in the cema-cel arm, compared to a 26.6% increase in the observation group.

The therapy was generally well tolerated, with no serious treatment-related adverse events reported and no cases of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. Ten of 12 patients in the treatment arm were managed entirely in outpatient settings, contrasting with broader CAR-T experiences where hospitalization rates typically range from 70% to 90%. Although based on a small sample size, baseline characteristics indicated that the cema-cel arm included a higher proportion of patients with more aggressive disease features.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) develops allogeneic CAR-T cell therapies for cancer and autoimmune diseases.

7. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

On April 16, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) will be presented on April 22 at the American Academy of Neurology Annual Meeting in Chicago. The data support the selection of the 10 mg dose for Phase 3 development. In the study, pilavapadin 10 mg demonstrated a nominally significant reduction in Average Pain at Week 8 versus placebo, along with consistent improvements in Worst and Least Daily Pain based on the Brief Pain Inventory-DPN. The treatment was generally well tolerated, with completion rates similar to placebo and few discontinuations due to adverse events.

At the same conference, the company will also present preclinical findings evaluating pilavapadin’s impact on spasticity-related endpoints in models of multiple sclerosis and spinal cord injury.

Last month, Lexicon and Novo Nordisk announced the initiation of a Phase 1 study for LX9851, an oral non-incretin candidate targeting obesity and related metabolic disorders. The program follows a March 2025 exclusive licensing agreement granting Novo Nordisk global rights to develop and commercialize the asset. Lexicon has received a second $10M milestone payment tied to initial dosing in the study and remains eligible for an additional $10M milestone later in 2026, as well as up to $1B in total milestone payments and tiered royalties on future sales.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) focuses on developing therapies for a range of diseases, including metabolic and neurological conditions.

6. New Era Energy & Digital, Inc. (NASDAQ:NUAI)

On April 15, 2026, Northland initiated coverage of New Era Energy & Digital, Inc. (NASDAQ:NUAI) with an Outperform rating and an $11 price target. The firm said the company has made “steady progress” since announcing its pivot into AI infrastructure in August 2025 and now appears positioned to secure its first lease by the fall. Northland views the company as an undervalued, early-stage AI infrastructure provider with key elements in place to execute.

Similarly, Texas Capital analyst Derrick Whitfield initiated coverage with a Buy rating and an $8.60 price target. The firm described New Era as a vertically integrated developer and operator of next-generation digital infrastructure and power assets, adding that it is well-positioned to land its first tenant at its Texas Critical Data Centers campus. Texas Capital estimates that securing a tenant could unlock roughly $3.50 per share in incremental upside.

Separately, the company announced the appointment of Andy Casazza as Chief Corporate Officer, effective April 28. He previously served as co-founder, CFO, and board member of Windy Cove Energy II and Pure Earth Plasma Holdings.

New Era Energy & Digital, Inc. (NASDAQ:NUAI) develops and operates digital infrastructure and integrated power solutions for AI-focused data center customers.

Click to continue reading and see the 5 Best Penny Stocks to Buy and Hold Under $5.

Disclosure: None. Follow Insider Monkey on Google News.